News
Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...
2d
MedPage Today on MSNMS Therapy Management for Pregnancy May Raise Relapse RiskCombining preconception, gestation, and postpartum periods, the total effect of pregnancy raised relapse rates (cRR 1.07, 95% ...
Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...
NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...
3d
MedPage Today on MSNSubcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New DataTORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...
Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...
In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...
Garonit Pharmaceutical, an India-based API maker, plans to build a $46.1 million production plant in New York to produce ...
New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments.
Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...
Biogen’s Qalsody (tofersen) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results